Apyx Medical: Power Lipo Delivers, but Cash Flow Promise Fades
AYON platform gains traction with power liposuction clearance, but the company pulls back from explicit Q4 2026 cash-flow positive guidance.
APYX · Earnings Call · 2026-08-06
The AYON Platform Adds a New Tool
Apyx Medical's second-quarter results (reported August 6) showed continued momentum behind its integrated body contouring platform. Revenue rose 22% year over year to $13.9 million, driven by a 28% jump in Surgical Aesthetics sales as Power Lipo handpiece shipments began. The company received expanded FDA clearance for power liposuction in May and started initial commercial shipments in June after a limited launch. On the call, CEO Charlie Goodwin said that the new handpiece was already embedded in full-year guidance, a change from prior quarters when it was treated as upside. “When you say embedded into the guidance, yes. I mean, Power Lipo is always something that we had anticipated to have in the back half of the year. And yes, it is in the guidance.” — Charles Goodwin, Chief Executive Officer · 2026-08-06 That contrast with the earlier stance—during the Q1 call, management had said the handpiece would be "on an upside basis" “the handpieces itself, those will be on an upside basis.” — Charles Goodwin, Chief Executive Officer · 2026-03-10—signals that the company now expects the accessory to contribute meaningfully to the back half of 2026. The reusability economics also matter: a busy practice may go through two to four handpieces per year, and AYON drives about $100 in recurring tubings and canisters per procedure, so the installed base becomes a consumable annuity.Cash Flow: A Softer Promise
The most notable shift this quarter may be in the company's cash-flow messaging. In March, CFO Matt Hill had stated the goal of being “cash flow positive no later than the fourth quarter of 2026.” — Matthew Hill, Chief Financial Officer · 2026-03-10 On this call, both executives used more cautious language: Hill said the company is “getting to cash flow positive as quickly as possible” — Matthew Hill, Chief Financial Officer · 2026-08-06 and that it expects to maintain liquidity into 2028. That is a more distant runway than the prior "through 2027" statement, but the explicit near-term profit target has been dropped. Investors looking for a hard date will find none. The company’s gross margin improved to 63.9% in the quarter, up from 62.3% a year ago, and adjusted EBITDA loss narrowed from $2.0 million to $0.7 million. Still, with cash and equivalents of $27.6 million and an operating loss of $1.8 million, the path to cash generation is more open-ended than previously telegraphed.Tariff Refunds and the GLP-1 Tailwind
Apyx joins a broad cohort of companies expecting IEEPA tariff refunds. In the Q&A, Goodwin acknowledged the expectation but kept it out of guidance: “We are in the process of going through that. We would expect to receive some, and we don't really have any idea exactly what that would be at this time. And if we did get any tariff refunds, they are not in the current guidance that is out there now.” — Charles Goodwin, Chief Executive Officer · 2026-08-06 The global keyword trajectory shows IEEPA tariff refund as a top theme across many reporters this quarter, so Apyx is riding a much larger wave of import-related reversals. The other major driver remains the GLP-1 wave. Management has consistently argued that weight-loss drugs create a population with loose skin and laxity, which is exactly what AYON and Renuvion address. The company’s own keyword history shows skin laxity recurring as a core theme. During the quarter, Apyx also published a retrospective study of 113 patients showing that combining Renuvion with liposuction produced statistically higher satisfaction and fewer revisions than liposuction alone, adding clinical ammunition for the procedure attachment rate. The stock remains under pressure, down roughly 21% over the past 90 days and still more than 80% below its 2021 peak. Yet the fundamentals are heading in the right direction: revenue growth accelerated, gross margin improved, and the AYON launch is broadening beyond the existing Renuvion base. The question is whether the company can convert that momentum into cash flow without further equity dilution.AYON is also starting to win over surgeons who had never used Renuvion, expanding the addressable market. The company plans to register the platform in key international markets—Europe, Latin America, and the Middle East—in the coming years, though the near-term focus remains the U.S.U.S. surgeons are increasingly recognizing the value of our integrated all-in-one body contouring platform, which combines the core technologies they rely on every single day into a single streamlined system.